Cynata Therapeutics Limited ( (AU:CYP) ) has issued an announcement.
Cynata Therapeutics Limited has established a new Scientific Advisory Board (SAB) composed of globally recognized experts in cell-based therapies. This board aims to provide strategic scientific guidance and oversight for the company’s research and development efforts. The SAB includes Professor John Rasko as Chair, Professor Igor Slukvin, and Dr. Derek Hei, all of whom have significant experience and contributions to the field. This move is expected to help Cynata maintain its leading position in iPSC-based therapeutic development, potentially impacting its operations and industry standing positively.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in stem cell and regenerative medicine. The company focuses on developing therapies using its proprietary Cymerus™ platform, which utilizes induced pluripotent stem cells (iPSCs) to produce cell therapy products, including mesenchymal stem cells (MSCs), at a commercial scale without the need for multiple donors. Cynata has shown positive results in Phase 1 clinical trials for its products CYP-001 and CYP-006TK, targeting conditions such as steroid-resistant acute graft versus host disease and diabetic foot ulcers.
YTD Price Performance: -27.89%
Average Trading Volume: 1,111
Technical Sentiment Signal: Strong Buy
Current Market Cap: $27M
For an in-depth examination of CYP stock, go to TipRanks’ Stock Analysis page.